Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Fidelity Biopharma Co. is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct art units, indicating that the company's pharmaceutical innovations are categorized into different technical niches. The prosecution involves 2 distinct examiners, providing a varied review process for the pending applications. This distribution suggests that the company's innovations span multiple technical classifications within the pharmaceutical field.
REI TSANG SHIAO is the busiest examiner for this portfolio, with 1 pending office action under review. This accounts for a portion of the 2 total pending actions. The fact that the pending office actions are split between 2 distinct examiners means that no single examiner has a majority of the workload. Practitioners should prepare for different examination styles as the examiners operate in different art units.
The distribution of 2 pending office actions across 2 distinct art units indicates that the legal strategy must be tailored to the specific requirements of each unit. With REI TSANG SHIAO handling 1 pending action, the portfolio's current momentum is divided across the involved personnel. This structure ensures that the company's success is not tied to the discretion of any one individual but is spread across 2 distinct examiners. Practitioners must manage these parallel tracks to ensure consistent results.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255601 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | DAHLIN, HEATHER RAQUEL | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255601 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | DAHLIN, HEATHER RAQUEL | 50d overdue |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18770456 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | SHIAO, REI TSANG | 1691 | §103DP | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18255601 | FOSPHENYTOIN SODIUM SOLID COMPOSITION, LYOPHILIZATION METHOD, AND USE OF FOSPHENYTOIN SODIUM SOLID COMPOSITION | DAHLIN, HEATHER RAQUEL | 1629 | §102§103§112 | Final Rejection | 50d overdue | Pending | Jun 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFidelity Biopharma Co. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rei Tsang Shiao has the most, with 1 of Fidelity Biopharma Co.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
